Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats  

作　　者：Yunzhen HU Minjuan ZUO Xiaojuan WANG Rongrong WANG Lu LI Xiaoyang LU Saiping JIANG 

机构地区：[1]Department of Clinical Pharmacy,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310006,China [2]Public Service Platform for the Evaluation of Innovative Drug Property,Hangzhou 311121,China

出　　处：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2021年第7期599-602,共4页浙江大学学报（英文版）B辑（生物医学与生物技术）

基　　金：the National Natural Science Foundation of China(No.81703612)。

摘　　要：The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-Co V-2) has occasioned worldwide alarm. Globally, the number of reported confirmed cases has exceeded 84.3 million as of this writing(January 2, 2021). Since there are no targeted therapies for COVID-19。

关 键 词：DRUGS ACUTE RESPIRATORY 

分 类 号：R965[医药卫生—药理学]